Cyclopharm (ASX:CYC) said its Technegas technology, which provides high-resolution ventilation imaging at the site where oxygen is taken up in the lung, received regulatory approval in Colombia, according to a Monday Australian bourse filing.
The company said it would work with local partners and clinical centers in Colombia to support education and clinical adoption.
Cyclopharm's shares rose past 5% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.